US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by Virios Therapeutics, Inc.

News headline image
Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
From Virios Therapeutics, Inc.
Via Business Wire
Tickers VIRI
News headline image
Virios Therapeutics, Inc. Announces Closing of Public Offering
From Virios Therapeutics, Inc.
Via Business Wire
Tickers VIRI
News headline image
Virios Therapeutics, Inc. Announces Pricing of Public Offering
From Virios Therapeutics, Inc.
Via Business Wire
Tickers VIRI
News headline image
Virios Therapeutics, Inc. Announces Proposed Public Offering
From Virios Therapeutics, Inc.
Via Business Wire
Tickers VIRI
News headline image
Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
From Virios Therapeutics, Inc.
Via Business Wire
Tickers VIRI
News headline image
Virios Therapeutics, Inc. to Present at Investor Summit Group’s Q3 Virtual Conference
From Virios Therapeutics, Inc.
Via Business Wire
Tickers VIRI
News headline image
Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022
From Virios Therapeutics, Inc.
Via Business Wire
Tickers VIRI
News headline image
Virios Therapeutics’ Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patients with Comorbid Fibromyalgia
From Virios Therapeutics, Inc.
Via Business Wire
Tickers VIRI
News headline image
Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
From Virios Therapeutics, Inc.
Via Business Wire
Tickers VIRI
News headline image
Virios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, 2022
From Virios Therapeutics, Inc.
Via Business Wire
Tickers VIRI
News headline image
Virios Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
From Virios Therapeutics, Inc.
Via Business Wire
Tickers VIRI
News headline image
Virios Therapeutics Granted New Patent for Antiviral Inhibitor Combination
From Virios Therapeutics, Inc.
Via Business Wire
Tickers VIRI
News headline image
Virios Therapeutics Announces New Social Media Profiles
From Virios Therapeutics, Inc.
Via Business Wire
Tickers VIRI
News headline image
Virios Therapeutics CEO Highlights Novel Therapeutic Approach for Treating Fibromyalgia and Irritable Bowel Syndrome in Stock News Now Video Interview
From Virios Therapeutics, Inc.
Via Business Wire
Tickers VIRI
News headline image
Virios Therapeutics Announces Second Quarter 2021 Financial Results and Provides Corporate Update
From Virios Therapeutics, Inc.
Via Business Wire
Tickers VIRI
News headline image
Virios Therapeutics Highlights Safety Data from Phase 2a Fibromyalgia Trial at the International Association for the Study of Pain (IASP) World Congress
From Virios Therapeutics, Inc.
Via Business Wire
Tickers VIRI
News headline image
Virios Therapeutics Announces Oral Presentation of Clinical Data at Digestive Disease Week® (DDW)
From Virios Therapeutics, Inc.
Via Business Wire
Tickers VIRI
News headline image
Virios Therapeutics to Present at the Benzinga Global Small Cap Conference
From Virios Therapeutics, Inc.
Via Business Wire
Tickers VIRI
News headline image
Virios Therapeutics to Present at the Needham Virtual Healthcare Conference
From Virios Therapeutics, Inc.
Via Business Wire
Tickers VIRI